Proteomic profiling platforms head to head: Leveraging genetics and clinical traits to compare aptamer- and antibody-based methods.
Daniel H KatzJeremy M RobbinsShuliang DengUsman A TahirAlexander G BickAkhil PampanaZhi YuDebby NgoMark D BensonZsu-Zsu ChenDaniel E CruzDongxiao ShenYan GaoClaude BouchardMark A SarzynskiAdolfo CorreaPradeep NatarajanJames G WilsonRobert E GersztenPublished in: Science advances (2022)
High-throughput proteomic profiling using antibody or aptamer-based affinity reagents is used increasingly in human studies. However, direct analyses to address the relative strengths and weaknesses of these platforms are lacking. We assessed findings from the SomaScan1.3K ( N = 1301 reagents), the SomaScan5K platform ( N = 4979 reagents), and the Olink Explore ( N = 1472 reagents) profiling techniques in 568 adults from the Jackson Heart Study and 219 participants in the HERITAGE Family Study across four performance domains: precision, accuracy, analytic breadth, and phenotypic associations leveraging detailed clinical phenotyping and genetic data. Across these studies, we show evidence supporting more reliable protein target specificity and a higher number of phenotypic associations for the Olink platform, while the Soma platforms benefit from greater measurement precision and analytic breadth across the proteome.